What do I need to provide to start a project?

To initiate a customized screening campaign, we require: Target Information: Accession number, protein sequence, or target cell line. Functional Requirements: Desired mechanism of action (e.g., neutralizing, depleting, or internalizing). Cross-reactivity Needs: Specific species requirements (e.g., Human/Mouse cross-reactivity).

Why choose a Premade Library for inflammatory cytokine targets?

Inflammatory cytokines (e.g., TNF, IL-6, IL-17) are often highly conserved between species, making them poor immunogens for animal-based discovery. Our Premade Phage & Yeast Display Human Libraries bypass immune tolerance, allowing for the rapid identification of high-affinity binders to these "self-antigens." Furthermore, the in vitro nature of our platform allows us to screen in specific buffers that mimic the acidic or protease-rich environment of inflamed tissues.

Can you identify antibodies that block specific ligand-receptor interactions?

Yes. We specialize in functional blocking (antagonistic) antibody discovery. By employing competitive elution strategies or using receptor-overexpressing cell lines in our yeast display platform, we can specifically select for clones that bind to the receptor-binding domain (RBD), effectively neutralizing the pro-inflammatory signaling cascade.

Are the discovered antibodies stable enough for high-concentration formulations?

Inflammation-related therapies often require subcutaneous injection at high concentrations. We address this early by: Biophysical Screening: Evaluating the solubility and aggregation propensity of lead clones. Thermal Stability: Measuring the melting temperature (Tm) to ensure long-term stability. Sequence Optimization: Removing potential post-translational modification (PTM) sites that could lead to heterogeneity.

Can you develop antibodies for G-Protein Coupled Receptors (GPCRs) involved in inflammation?

GPCRs and ion channels are notoriously difficult targets due to their complex transmembrane structures. We utilize Phage Display and Yeast Display paired with cell lines, Nanodiscs or Virus-Like Particles (VLPs) to present these receptors in their native, functional conformation, ensuring the discovery of antibodies that recognize the target as it appears on the cell surface.

Inflammation Disease Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Overcome the persistent hurdles of high sequence homology and immune tolerance that often derail traditional antibody discovery. At Creative Biolabs, we provide a strategic shortcut to functional excellence by leveraging our massive premade antibody libraries. By combining surgical screening precision with early-stage functional validation, we deliver high-affinity, clinical-ready candidates in a fraction of the traditional timeline.

Have Questions? Get a Quote Tailored to Your Needs

Strategic Antibody Discovery for Complex Inflammatory Targets

Inflammatory mediators, ranging from pleiotropic cytokines to complex chemokine receptors, present a unique set of biological hurdles. These include high sequence homology between species, rapid protein turnover, and the absolute requirement for potent functional neutralization. Traditional immunization often struggles to break immune tolerance or yield effective blocking antibodies against these conserved targets.

Creative Biolabs overcomes these limitations by utilizing hyper-diverse premade human libraries with a complexity of 10¹¹ variants. By employing mechanism-centric screening, we bypass the constraints of in vivo systems to deliver high-affinity, developable antagonists and specific binders. Our platform is designed to provide preclinical-ready candidates in weeks rather than months.

Let's Talk. Request a Quote for Your Project

Workflow

Discovery Design & Antigen Strategy

Homology modeling; selection of bioactive cytokines/receptors; decoy strategy for isoform specificity; planning for soluble vs. membrane targets.
Biopanning & Enrichment

Up to 4-5 rounds of competitive panning; receptor-blocking elution to favor antagonists; high-stringency washing; depletion of non-specific binders.
Single-Clone Screening & Specificity De-risking

High-throughput validation; cross-reactivity profiling against homologous cytokines/receptors; early non-specific binding triage.
Functional Selection & Epitope Strategy

Cell-based receptor blocking assays; reporter gene assays for signaling inhibition; epitope binning to ensure diverse mechanisms.
Sequence Analytics & Liability Filtering

NGS-driven clonotype clustering; in silico liability screens; framework optimization paths.
Expression, IgG Conversion & Developability Panel

Mini-panel IgG expression; biophysical profiling (solubility, thermal stability, pH stability).

Send Your Requirements. Receive a Quote

Ready-to-Screen Antibody Libraries

Our libraries are engineered for developability, featuring proven frameworks and massive diversity to capture rare, high-potency binders against difficult inflammatory targets. Find the options below to find the best match for your specific inflammation disease target.

Human Camel Llama Alpaca Humanized V_HH

Antibody Library ID	Display Technology	Library Format	Library Size
HuScL-6 ☆Highly Recommended	pIII-fusion, Phagemid Phage Display	Naïve scFv	2.1×10¹¹
HuScL-3S	pIII-fusion, Phagemid Phage Display	Semi-synthetic scFv	>1.0×10¹¹
HuFabL-4	pIII-fusion, Phagemid Phage Display	Naïve Fab	1.9×10¹⁰
HuFabssL-1	pIII-fusion, Phagemid Phage Display	Naïve & synthetic Fab	1.8×10¹⁰

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Discovery of Species Cross-Reactive Antibodies Against a Critical Pro-inflammatory Biomarker
Objective	In the therapeutic landscape of chronic inflammatory disorders and systemic fibrosis, certain secreted glycoproteins (such as specific Galectin-binding proteins) have emerged as pivotal targets due to their role in driving pro-inflammatory cytokine cascades. A significant challenge in drug discovery for these targets is the requirement for leads that maintain high clinical relevance (Human target) while exhibiting robust species cross-reactivity (Mouse ortholog) to facilitate in vivo efficacy and safety validation in murine models. This case study highlights our success in utilizing a Premade Synthetic Human Antibody Library to isolate high-affinity candidates with defined species-binding profiles, supported by technical consultancy.
Strategic Approach	To meet these dual objectives, our team implemented a Target-Driven Screening with Parallel Diversity Identification strategy using our Premade Synthetic Human Antibody Library. 1. Pre-discovery Support We conducted an in-depth bioinformatics alignment of the human and murine protein sequences, identifying conserved domains to evaluate the feasibility of cross-reactive discovery. We also provided guidance on antigen quality control, ensuring the proteins maintained native glycosylation patterns. 2. Selection Strategy High-Stringency Panning Initial selection cycles were performed against the Human target protein to prioritize clones with the highest clinical potential. Differential Identification During the screening phase, we performed parallel profiling against both human and murine antigens. This allowed us to stratify the candidates into Human-specific binders and Human/Mouse cross-reactive binders, providing the client with a versatile asset pool.
Key Results & Validation Data	1. Robust Library Enrichment The selection process demonstrated a clear increase in phage recovery across successive rounds, indicating successful library convergence toward high-affinity epitopes on the pro-inflammatory target. Figure 7. Enrichment Profile Against Human Target. The chart illustrates the significant increase in the Output/Input ratio over three rounds of panning, confirming the efficient recovery of target-specific binders from the synthetic library. 2. Primary Monoclonal Identification (Phage ELISA) Large-scale monoclonal screening of the enriched pool revealed a diverse repertoire of binders with distinct species-binding characteristics. Figure 8. Monoclonal Specificity Profiling via Phage ELISA. Primary screening categorized the enriched repertoire into two distinct populations: cross-reactive clones with high-affinity binding to both human and murine orthologs, and human-specific clones with no detectable cross-reactivity. This divergence enables precise candidate selection tailored to specific preclinical or clinical objectives. 3. Functional Validation of Soluble Binders Following small-scale expression in full-length IgG format, the biochemical potency and species-binding profiles of the lead candidates were rigorously verified. Figure 9. Validation of Cross-Reactive Potential via Binding ELISA. Comparative binding assays confirm that the lead cross-reactive clone maintains high-level, equilibrated affinity for both human and murine orthologs in its soluble IgG form, validating its suitability for in vivo murine modeling.
Technical Support	Upstream Support Provided strategic consultancy on antigen design and the implementation of subtractive panning techniques to minimize off-target reactivity with homologous protein families. Downstream Support Conducted Developability Assessment (PTM analysis) of CDR sequences and provided engineering recommendations for isotype switching (e.g., conversion to full IgG) to align with desired effector functions in fibrosis research.

Have a Deadline? Get Expedited Pricing

Related Services

Fig.10 Anti-Disease-specific Target Antibody Discovery. (Creative Biolabs Authorized)

Anti-tumor-specific Target Antibody Discovery

Anti-infectious disease-specific Antibody Discovery

Anti-autoimmune disorder-specific Antibody Discovery

Anti-allograft rejection-specific Antibody Discovery

Why Choose Us?

Hyper-Diverse 10¹¹ Human Antibody Repertoires

We leverage proprietary, fully human phage display libraries with a massive complexity of 10¹¹ variants. In the context of inflammatory diseases, this immense diversity is critical for:

Targeting Pleiotropic Cytokines: Ensuring comprehensive coverage of multiple signaling surfaces.
Rare Clone Identification: Increasing the statistical probability of capturing rare neutralizing antibodies that bind to cryptic or transiently exposed epitopes often missed by smaller libraries.

Bypassing Immune Tolerance & Homology Constraints

Many inflammatory mediators (e.g., TNF-family ligands, interleukins) exhibit high sequence conservation across species, often leading to poor immunogenicity or "self-antigen" suppression in animal models.

In Vitro Advantage: Our premade human libraries bypass the biological limitations of in vivo systems.
Conserved Epitope Mapping: We successfully identify high-affinity antibodies against highly conserved epitopes, providing a seamless bridge from discovery to preclinical animal models without the need for surrogate antibodies.

Precision Engineering for Complex Membrane Targets

Inflammation is often driven by complex membrane proteins, such as GPCRs (Chemokine Receptors) and multi-pass ion channels. Our platform excels where others struggle:

Cell-Based Panning: We utilize specialized Whole-Cell Panning to ensure antibodies recognize the target in its native, post-translationally modified conformation.
Subtractive Selection: By employing sophisticated subtraction strategies against homologous non-target proteins, we eliminate off-target binders early, ensuring absolute specificity within protein families.

Function-First: A Strategic Filtration Engine

We don't just find binders; we discover biological modulators. Our screening process acts as a strategic filtration engine tailored for anti-inflammatory efficacy: We integrate competitive elution and blockade-verified panning to prioritize clones that actively interrupt ligand-receptor interactions. By focusing on functional antagonism rather than simple surface binding, we deliver leads characterized by their potent ability to suppress inflammatory signaling pathways.

Customize Your Package - Get Pricing

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

What do I need to provide to start a project?
To initiate a customized screening campaign, we require: Target Information: Accession number, protein sequence, or target cell line. Functional Requirements: Desired mechanism of action (e.g., neutralizing, depleting, or internalizing). Cross-reactivity Needs: Specific species requirements (e.g., Human/Mouse cross-reactivity).
Why choose a Premade Library for inflammatory cytokine targets?
Inflammatory cytokines (e.g., TNF, IL-6, IL-17) are often highly conserved between species, making them poor immunogens for animal-based discovery. Our Premade Phage & Yeast Display Human Libraries bypass immune tolerance, allowing for the rapid identification of high-affinity binders to these "self-antigens." Furthermore, the in vitro nature of our platform allows us to screen in specific buffers that mimic the acidic or protease-rich environment of inflamed tissues.
Can you identify antibodies that block specific ligand-receptor interactions?
Yes. We specialize in functional blocking (antagonistic) antibody discovery. By employing competitive elution strategies or using receptor-overexpressing cell lines in our yeast display platform, we can specifically select for clones that bind to the receptor-binding domain (RBD), effectively neutralizing the pro-inflammatory signaling cascade.
Are the discovered antibodies stable enough for high-concentration formulations?
Inflammation-related therapies often require subcutaneous injection at high concentrations. We address this early by: Biophysical Screening: Evaluating the solubility and aggregation propensity of lead clones. Thermal Stability: Measuring the melting temperature (Tm) to ensure long-term stability. Sequence Optimization: Removing potential post-translational modification (PTM) sites that could lead to heterogeneity.
Can you develop antibodies for G-Protein Coupled Receptors (GPCRs) involved in inflammation?
GPCRs and ion channels are notoriously difficult targets due to their complex transmembrane structures. We utilize Phage Display and Yeast Display paired with cell lines, Nanodiscs or Virus-Like Particles (VLPs) to present these receptors in their native, functional conformation, ensuring the discovery of antibodies that recognize the target as it appears on the cell surface.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: